Genome-wide analyses of leukemia-associated genes in cases of recurrence have revealed that recurrent tumor cells generally express genes associated with resistance to cytotoxic chemotherapeutic treatment such as NT5C2 and MSH6 together with changes in the activation of many pathways such as the JAK/STAT and MAPK pathways. This evidence concerns the gene MSH6 and neoplasm.